Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Lantheus stock

Learn how to easily invest in Lantheus stock.

Lantheus Holdings Inc
NASDAQ: LNTH - USD
$68.36
- $2.46 ( - 3.47%)
DRUG MANUFACTURERS-SPECIALTY & GENERIC

Lantheus Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Lantheus shares (LNTH) are listed on the NASDAQ and all prices are listed in US Dollars. Lantheus employs 612 staff and has a trailing 12-month revenue of around $664.2 million.

How to buy shares in Lantheus

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LNTH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Lantheus stock price (NASDAQ: LNTH)

Use our graph to track the performance of LNTH stocks over time.

Lantheus shares at a glance

Information last updated 2022-09-25.
Latest market close$68.36
52-week range$22.20 - $87.47
50-day moving average $78.33
200-day moving average $56.10
Wall St. target price$103.20
PE ratio 175.2821
Dividend yield $0 (0%)
Earnings per share (TTM) $0.39

Buy Lantheus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lantheus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lantheus price performance over time

Historical closes compared with the close of $68.36 from 2022-09-23

1 week (2022-09-19) -11.45%
1 month (2022-08-26) -16.13%
3 months (2022-06-24) 8.82%
6 months (2022-03-23) 23.17%
1 year (2021-09-24) 153.47%
2 years (2020-09-25) 460.33%
3 years (2019-09-26) 162.02%
5 years (2017-09-26) 291.75%

Is Lantheus stock undervalued or overvalued?

Valuing Lantheus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lantheus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Lantheus's P/E ratio

Lantheus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 175x. In other words, Lantheus shares trade at around 175x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Lantheus's PEG ratio

Lantheus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lantheus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Lantheus's EBITDA

Lantheus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $200.8 million.

The EBITDA is a measure of a Lantheus's overall financial performance and is widely used to measure a its profitability.

Lantheus financials

Revenue TTM $664.2 million
Operating margin TTM 22.94%
Gross profit TTM $187.7 million
Return on assets TTM 10.18%
Return on equity TTM 6.02%
Profit margin 4.88%
Book value $8.26
Market capitalisation $4.7 billion

TTM: trailing 12 months

Lantheus share dividends

We're not expecting Lantheus to pay a dividend over the next 12 months.

Lantheus share price volatility

Over the last 12 months, Lantheus's shares have ranged in value from as little as $22.2 up to $87.47. A popular way to gauge a stock's volatility is its "beta".

LNTH.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantheus's is 0.7727. This would suggest that Lantheus's shares are less volatile than average (for this exchange).

Lantheus overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.

Frequently asked questions

What percentage of Lantheus is owned by insiders or institutions?
Currently 2.445% of Lantheus shares are held by insiders and 101.293% by institutions.
How many people work for Lantheus?
Latest data suggests 612 work at Lantheus.
When does the fiscal year end for Lantheus?
Lantheus's fiscal year ends in December.
Where is Lantheus based?
Lantheus's address is: 331 Treble Cove Road, North Billerica, MA, United States, 01862
What is Lantheus's ISIN number?
Lantheus's international securities identification number is: US5165441032
What is Lantheus's CUSIP number?
Lantheus's Committee on Uniform Securities Identification Procedures number is: 516544103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site